The India intravenous solution market size reached US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 1.8 Billion |
Market Forecast in 2032
|
US$ 2.9 Billion |
Market Growth Rate (2024-2032) | 5.1% |
Intravenous (IV) solutions are a mix of essential nutrients that replenish fluid loss and treat electrolyte imbalances in IV therapy. They are administered into the venous circulation with the help of a syringe or IV catheter. IV solutions are made of electrolytes, sugar, and medications required by patients suffering from diabetes, cancer and other diseases. They also provide nutrients added in concentrations as per the patient’s medical condition, age, and size.
India represents one of the largest markets for IV solutions, primarily driven by the increasing population and the rising prevalence of gastrointestinal diseases, neurological disorders, and diabetes. This is due to unhealthy eating habits and sedentary lifestyles. Besides this, various government initiatives related to improving the healthcare infrastructure of the country are also propelling the growth of the market. Additionally, the growing consciousness among individuals regarding their health and the increasing disposable incomes of consumers have enabled them to expand healthcare expenditure, thereby positively impacting the market growth. Furthermore, the availability of these solutions in portable packages has made it easier for patients to use drips in their home’s comfort.
IMARC Group provides an analysis of the key trends in each sub-segment of the India intravenous solution market report, along with forecasts at the country and regional levels from 2024-2032. Our report has categorized the market based on type and nutrients.
Breakup by Type:
Breakup by Nutrients:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Billion |
Segment Coverage | Type, Nutrients, Region |
Region Covered | North India, West and Central India, South India, East India |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 2699 Five User License: US$ 3699 Corporate License: US$ 4699 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The India intravenous solution market was valued at US$ 1.8 Billion in 2023.
We expect the India intravenous solution market to exhibit a CAGR of 5.1% during 2024-2032.
The increasing prevalence of chronic diseases, along with the escalating demand for intravenous solutions, as they provide faster response time and higher efficacy than other drug delivery systems, is primarily driving the India intravenous solutions market.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of intravenous solutions across the nation for providing essential nutrients to the coronavirus-infected patients that are admitted in the Intensive Care Unit (ICU).
Based on the type, the India intravenous solution market has been segmented into partial parenteral nutrition and total parenteral nutrition. Currently, total parenteral nutrition exhibits a clear dominance in the market.
Based on the nutrients, the India intravenous solution market can be bifurcated into carbohydrates, salts and electrolytes, minerals, vitamins, and amino acids. Among these, salts and electrolytes account for the majority of the total market share.
On a regional level, the market has been classified into North India, West and Central India, South India, and East India, where West and Central India currently dominates the India intravenous solution market.